MHRA

Richmond Pharmacology, the 1st Early Phase CRO to receive MHRA Standard and Supplementary Accreditation for 2 hospital based Clinical Trial Centers.Richmond Pharmacology. (RPL) have proudly received MHRA Standard and Supplementary Accreditation, a clear sign of our continued commitment to providing the highest level of subject safety on all studies conducted within our two hospital based Early Phase trial centres. RPL is unique in being the only Early Phase CRO in the UK to have two trial centres based in two acute NHS teaching hospitals.The supplementary accreditation confirms that RPL have attained the highest level of accreditation available in Europe. This permits RPL to perform the full range of Early Phase studies, including trials requiring a review of risk factors by the Expert Advisory Group (EAG).The combination of this accreditation award, our experience from conducting in excess of 400 Early Phase studies and our world-leading scientific advisory board means our sponsors can rely on RPL to continue to lead the industry in the conduct of FTIM studies, as well as other specialty areas such as TQT Studies, Japanese bridging studies, gastrointestinal studies and patient studies.For more information on the MHRA Phase I accreditation scheme visit the MHRA website.For further information on RPL's Early Phase facilities and expertise,please review our brochures.

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5

Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

1. Item 1
2. Item 2
3. Item 3

Unordered list

• Item A
• Item B
• Item C

Text link

Bold text

Emphasis

^Superscript

_Subscript